BioSpace News Archive

Through Triple Play, Boys & Girls Clubs of America and Anthem Blue Cross and Blue Shield Foundation are delivering education and programming that promotes the importance of physical activity and proper nutrition, and enables youth to build the skills needed to overcome environmental factors that can negatively impact health and wellness.

ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the achievement of major milestones in its clinical trial programs.

BryoLogyx, a privately held company focused on improving on survival rates for patients with cancer announced today it has acquired exclusive rights from Stanford University for synthetic bryostatin-1 and a wide range of bryostatin analogues.

Economic growth in the United States will continue in 2019, say the nation’s purchasing and supply management executives in the December 2018 Semiannual Economic Forecast.

Interest in obesity medicine continues to rise as nearly 900 physicians apply for certification.

Pharmacy Times Continuing Education™ (PTCE), a leader in continuing education for retail, health system, managed care and specialty pharmacists, announced The Council for Medication Safety: Mitigating Contamination and Improving the Safe Handling of Hazardous Drugs on Wednesday, Nov. 7, at the 36th Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow® meeting.

Barclays announces the appointment of David Parrot as Managing Director and Head of Barclays’ US West Coast Biotech Banking franchise.

ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces that its SOZO® Digital Health Platform was awarded the top distinction in a competitive field of ABBY-nominated semi-finalists at the ABL Organization’s 19th Innovations in Healthcare ABBY Awards

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs

Immix Biopharma, Inc announced today positive interim results from its ongoing phase 1b/2a study testing IMX-110 in advanced solid tumors. Immix observed Stable Disease at cohort (dose-level) 2 in a middle-aged male with stage IV colorectal cancer that was refractory to radiation therapy, chemotherapy and immunotherapy.